Clinical Trial Update: A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis. [Phase 3]

View source ↗

Summary

A Phase III clinical study evaluating QY201 Tablet in adults with moderate to severe atopic dermatitis is currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• QY201 Tablet

Snippet

Sponsor: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. | Conditions: Atopic Dermatitis (AD) | Phase 3 | Status: ENROLLING_BY_INVITATION